Given recommendations from professional practice guidelines to select NSCLC patients with high PD-L1 expression for pembrolizumab, this real-world treatment cohort was biased for PD-L1 high-expressing tumors (82.3% of patients). This evidence concerns the gene CD274 and non-small cell lung carcinoma.